[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA54543A - Inhibiteurs de kif18a - Google Patents

Inhibiteurs de kif18a

Info

Publication number
MA54543A
MA54543A MA054543A MA54543A MA54543A MA 54543 A MA54543 A MA 54543A MA 054543 A MA054543 A MA 054543A MA 54543 A MA54543 A MA 54543A MA 54543 A MA54543 A MA 54543A
Authority
MA
Morocco
Prior art keywords
kif18a
inhibitors
kif18a inhibitors
Prior art date
Application number
MA054543A
Other languages
English (en)
Inventor
Abhisek Banerjee
Matthew Paul Bourbeau
James Alexander Brown
Jian Jeffrey Chen
Michael J Frohn
Lei Jia
Kexue Li
Qingyian Liu
Jonathan Dante Low
Vu Ma
Ana Elena Minatti
Liping H Pettus
Nuria A Tamayo
Mary Catherine Walton
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA54543A publication Critical patent/MA54543A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA054543A 2018-12-20 2019-12-20 Inhibiteurs de kif18a MA54543A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862783061P 2018-12-20 2018-12-20

Publications (1)

Publication Number Publication Date
MA54543A true MA54543A (fr) 2022-03-30

Family

ID=69187977

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054543A MA54543A (fr) 2018-12-20 2019-12-20 Inhibiteurs de kif18a

Country Status (24)

Country Link
US (3) US11236069B2 (fr)
EP (1) EP3897852A1 (fr)
JP (1) JP7407196B2 (fr)
KR (1) KR20210106474A (fr)
CN (1) CN113226473A (fr)
AR (1) AR117490A1 (fr)
AU (1) AU2019403486A1 (fr)
BR (1) BR112021011989A2 (fr)
CA (1) CA3123871A1 (fr)
CL (1) CL2021001634A1 (fr)
CO (1) CO2021008224A2 (fr)
CR (1) CR20210387A (fr)
EA (1) EA202191730A1 (fr)
IL (1) IL283639B2 (fr)
JO (1) JOP20210154B1 (fr)
MA (1) MA54543A (fr)
MX (1) MX2021007156A (fr)
PE (1) PE20211475A1 (fr)
PH (1) PH12021551409A1 (fr)
SA (1) SA521422303B1 (fr)
SG (1) SG11202106520VA (fr)
TW (1) TWI844602B (fr)
UY (1) UY38526A (fr)
WO (1) WO2020132648A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3123227A1 (fr) * 2018-12-20 2020-06-25 Amgen Inc. Amides d'heteroaryle utiles en tant qu'inhibiteurs de kif18a
BR112021011989A2 (pt) 2018-12-20 2021-09-08 Amgen Inc. Inibidores de kif18a
MX2022012992A (es) * 2020-04-14 2022-11-08 Amgen Inc Inhibidores de kif18a para el tratamiento de enfermedades neoplasicas.
EP4237086A1 (fr) 2020-10-27 2023-09-06 Amgen Inc. Composés spiro hétérocycliques et procédés d'utilisation
MX2023012725A (es) 2021-04-29 2024-09-23 Amgen Inc Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos.
EP4361142A1 (fr) 2021-06-25 2024-05-01 Hangzhou Innogate Pharma Co., Ltd. Composé destiné à être utilisé en tant qu'inhibiteur de kif18a
TW202321213A (zh) 2021-07-21 2023-06-01 美商安進公司 Ｋｉｆ１８ａ抑制劑化合物之鹽和固態形式
IL310863A (en) * 2021-08-26 2024-04-01 Volastra Therapeutics Inc KIF18A inhibitors in the spiro indoline form
KR20240108489A (ko) 2021-11-19 2024-07-09 위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드 Kif18a 저해제
KR20240144140A (ko) * 2022-01-26 2024-10-02 암젠 인코포레이티드 Kif18a 억제제의 합성
WO2023159086A1 (fr) 2022-02-16 2023-08-24 Amgen Inc. Composés de quinazoline et leur utilisation en tant qu'inhibiteurs de protéines kras mutantes
MX2024010043A (es) 2022-02-16 2024-08-26 Amgen Inc Compuestos de quinazolina y uso de los mismos como inhibidores de proteinas kras mutantes.
EP4495113A1 (fr) * 2022-03-17 2025-01-22 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Inhibiteur de kif18a
WO2023198209A1 (fr) * 2022-04-15 2023-10-19 武汉人福创新药物研发中心有限公司 Inhibiteur de kif18a et son utilisation
CN116514777B (zh) * 2022-05-13 2024-07-19 上海湃隆生物科技有限公司 驱动蛋白kif18a抑制剂及其应用
TW202400582A (zh) * 2022-05-13 2024-01-01 大陸商上海湃隆生物科技有限公司 驅動蛋白kif18a抑制劑及其應用
TW202408506A (zh) 2022-06-30 2024-03-01 大陸商勤浩醫藥(蘇州)有限公司 一種含氮化合物及其應用
WO2024032661A1 (fr) * 2022-08-11 2024-02-15 山东轩竹医药科技有限公司 Inhibiteur de kif18a et son utilisation
WO2024035950A1 (fr) * 2022-08-12 2024-02-15 Accent Therapeutics, Inc. Inhibiteurs de kif18a et leurs utilisations
WO2024039829A1 (fr) * 2022-08-18 2024-02-22 Accent Therapeutics, Inc. Inhibiteurs de kif18a et leurs utilisations
TW202413334A (zh) * 2022-09-08 2024-04-01 大陸商長春金賽藥業有限責任公司 Ｋｉｆ１８ａ抑制劑化合物、藥物組合物及其製備方法和用途
WO2024051812A1 (fr) * 2022-09-09 2024-03-14 先声再明医药有限公司 Composé amide, composition et utilisation correspondante
WO2024067675A1 (fr) * 2022-09-30 2024-04-04 长春金赛药业有限责任公司 Composé inhibiteur de kif18a à cycle condensé, composition pharmaceutique, procédé de préparation correspondant et utilisation associée
WO2024067465A1 (fr) * 2022-09-30 2024-04-04 山东轩竹医药科技有限公司 Inhibiteur de kif18a
CN117917405A (zh) * 2022-10-21 2024-04-23 杭州邦顺制药有限公司 Kif18a蛋白抑制剂
WO2024109923A1 (fr) * 2022-11-24 2024-05-30 InventisBio Co., Ltd. Composés hétérocycliques, leurs procédés de préparation et leurs utilisations
CN115594664B (zh) * 2022-11-25 2023-02-24 英矽智能科技(上海)有限公司 一类螺环衍生物作为kif18a抑制剂
WO2024114730A1 (fr) * 2022-11-30 2024-06-06 微境生物医药科技(上海)有限公司 Composition pharmaceutique pour le traitement du cancer
TW202430166A (zh) * 2022-12-02 2024-08-01 大陸商深圳眾格生物科技有限公司 醯胺或脲類化合物
WO2024125488A1 (fr) * 2022-12-14 2024-06-20 浙江海正药业股份有限公司 Dérivé d'amide aromatique, son procédé de préparation et son utilisation pharmaceutique
WO2024125626A1 (fr) * 2022-12-16 2024-06-20 Nuphase Therapeutics (Hangzhou) Limited., Co. Composé azoté, composition pharmaceutique et utilisation associée
WO2024137984A1 (fr) * 2022-12-22 2024-06-27 Accent Therapeutics, Inc. Inhibiteurs de kif18a et utilisations associées
WO2024140799A1 (fr) * 2022-12-28 2024-07-04 Insilico Medicine Ip Limited Inhibiteurs de kif18a et utilisations associées
WO2024146593A1 (fr) * 2023-01-05 2024-07-11 浙江海正药业股份有限公司 Dérivé d'amide aromatique, son procédé de préparation et son utilisation médicale
TW202434237A (zh) * 2023-01-20 2024-09-01 香港商英矽智能科技知識產權有限公司 Kif18a之抑制劑及其用途
CN118598855A (zh) * 2023-03-06 2024-09-06 武汉人福创新药物研发中心有限公司 抑制kif18a的化合物及其用途
CN115947717B (zh) * 2023-03-09 2023-05-30 英矽智能科技(上海)有限公司 一类kif18a抑制剂
WO2024217348A1 (fr) * 2023-04-18 2024-10-24 南京同诺康医药科技有限公司 Inhibiteur de kif18a, son procédé de préparation et son utilisation
CN116535400B (zh) * 2023-04-26 2024-08-16 上海湃隆生物科技有限公司 氮杂螺环化合物及其应用
WO2025026392A1 (fr) * 2023-08-02 2025-02-06 上海湃隆生物科技有限公司 Inhibiteur de kinésine kif18a et son utilisation

Family Cites Families (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
DE3381783D1 (de) 1982-03-03 1990-09-13 Genentech Inc Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
JP2762522B2 (ja) 1989-03-06 1998-06-04 藤沢薬品工業株式会社 血管新生阻害剤
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
DE69334100T2 (de) 1992-11-13 2007-07-19 Immunex Corp., Seattle Elk ligand, ein cytokin
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
JPH08503971A (ja) 1993-10-01 1996-04-30 チバ−ガイギー アクチェンゲゼルシャフト ピリミジンアミン誘導体及びその調製のための方法
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JP4105761B2 (ja) 1993-11-19 2008-06-25 アボット・ラボラトリーズ ラパミシン（マクロライド）の半合成類似体免疫調節剤
DK0734389T3 (da) 1993-12-17 2000-08-21 Novartis Ag Rapamycinderivater, som er anvendelige som immunosuppressive midler
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
CA2189028A1 (fr) 1994-04-15 1995-10-26 Gary M. Fox Nouvelles proteines tyrosine kinases receptrices analogues a l'eph, du type hek5, hek7, hek8, hek11
DE59500788D1 (de) 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
EP1110953B1 (fr) 1995-03-30 2009-10-28 Pfizer Products Inc. Dérivés de quinazolinone
JP4249804B2 (ja) 1995-04-03 2009-04-08 ノバルティス・アクチエンゲゼルシャフト ピラゾール誘導体およびその製造法
JP3053222B2 (ja) 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5650415A (en) 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
CN1124276C (zh) 1995-06-09 2003-10-15 诺瓦蒂斯有限公司 雷帕霉素衍生物
DK0836605T3 (da) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
AU1441497A (en) 1996-01-23 1997-08-20 Novartis Ag Pyrrolopyrimidines and processes for their preparation
JP3406763B2 (ja) 1996-01-30 2003-05-12 東レ・ダウコーニング・シリコーン株式会社 シリコーンゴム組成物
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19629652A1 (de) 1996-03-06 1998-01-29 Thomae Gmbh Dr K 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19608588A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6051577A (en) 1996-03-15 2000-04-18 Novartis Ag N-7-heterocyclyl pyrrolo[2,3-D]pyrimidines and the use thereof
DE69710712T3 (de) 1996-04-12 2010-12-23 Warner-Lambert Co. Llc Umkehrbare inhibitoren von tyrosin kinasen
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
DE69734513T2 (de) 1996-06-24 2006-07-27 Pfizer Inc. Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten
WO1998002441A2 (fr) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Elements et procedes pour traiter ou prevenir les mycoses pathogènes
EP0818442A3 (fr) 1996-07-12 1998-12-30 Pfizer Inc. Dérivés cycliques de sulfones comme inhibiteurs de métalloprotéinase et de la production du facteur de nécrose des tumeurs
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ID19609A (id) 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
AR007855A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
WO1998003516A1 (fr) 1996-07-18 1998-01-29 Pfizer Inc. Composes a base de phosphinate inhibiteurs des metalloproteases matricielles
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
ES2308787T3 (es) 1996-08-16 2008-12-01 Schering Corporation Antigenos de superficie de celular de mamiferos; reactivos relacionados.
EP0938486B1 (fr) 1996-08-23 2008-01-16 Novartis AG Pyrrolopyrimidines substituees et procede pour leur preparation
CA2264284A1 (fr) 1996-08-23 1998-02-26 Ralph P. Robinson Derives de l'acide arylsulfonylamino hydroxamique
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
JP4205168B2 (ja) 1996-10-02 2009-01-07 ノバルティス アクチエンゲゼルシヤフト ピリミジン誘導体およびその製造法
AU4779897A (en) 1996-10-02 1998-04-24 Novartis Ag Fused pyrazole derivatives and processes for their preparation
EP0837063A1 (fr) 1996-10-17 1998-04-22 Pfizer Inc. Dérivés de 4-aminoquinazoline
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
WO1998030566A1 (fr) 1997-01-06 1998-07-16 Pfizer Inc. Derives de sulfone cyclique
BR9807815A (pt) 1997-02-03 2000-03-08 Pfizer Prod Inc Derivados de ácido arilsulfonilamino-hidroxâmico
BR9807305A (pt) 1997-02-05 2000-05-02 Warner Lambert Co Pirido [2,3-d] pirimidinas e 4-aminopirimidinas como inibidores de proliferação celular.
EP0966438A1 (fr) 1997-02-07 1999-12-29 Pfizer Inc. Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices
YU37499A (sh) 1997-02-11 2002-09-19 Pfizer Inc. Derivati arilsulfonil hidroksamske kiseline
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6150395A (en) 1997-05-30 2000-11-21 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
AU8689298A (en) 1997-08-05 1999-03-01 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
ES2216293T3 (es) 1997-08-08 2004-10-16 Pfizer Products Inc. Derivados de acido ariloxiarilsulfonilamino-hidroxamico.
CA2308114A1 (fr) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Proteines tr11, tr11sv1 et tr11sv2 de type recepteur du facteur de necrose tumorale humain
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
CA2319236A1 (fr) 1998-02-09 1999-08-12 Genentech, Inc. Nouveaux homologues recepteurs du facteur necrosant des tumeurs et acides nucleiques codant ceux-ci
ES2324846T3 (es) 1998-03-04 2009-08-17 Bristol-Myers Squibb Company Inhibidores de la proteina tirosina quinasa de imidazopirazina heterociclo-sustituida.
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PT2020408E (pt) 1998-05-29 2013-09-13 Sugen Inc Inibidor de proteína cinase de 2-indolinona substituída com pirrole
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
JP2002520324A (ja) 1998-07-10 2002-07-09 メルク エンド カムパニー インコーポレーテッド 新規な血管形成インヒビター
JP2002523459A (ja) 1998-08-31 2002-07-30 メルク エンド カムパニー インコーポレーテッド 新規血管形成阻害剤
ATE260255T1 (de) 1998-11-05 2004-03-15 Pfizer Prod Inc 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
AU2725000A (en) 1999-01-13 2000-08-01 Bayer Corporation Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
DE60028740T2 (de) 1999-03-30 2007-05-24 Novartis Ag Phthalazinderivate zur behandlung von entzündlichen erkrankungen
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
JP4587626B2 (ja) 1999-06-07 2010-11-24 イミュネックス・コーポレーション Ｔｅｋアンタゴニスト
CA2378179A1 (fr) 1999-07-12 2001-01-18 Genentech, Inc. Stimulation ou inhibition de l'angiogenese et de la cardiovascularisation avec des homologues de ligands et de recepteurs du facteur de necrose tumorale
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
DK1676845T3 (da) 1999-11-05 2008-09-15 Astrazeneca Ab Nye quinazolinderivater
WO2001037820A2 (fr) 1999-11-24 2001-05-31 Sugen, Inc. Formulations pour agents pharmaceutiques ionisables comme acides libres ou bases libres
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
EP1259595B1 (fr) 2000-02-25 2007-04-04 Immunex Corporation Antagonistes des integrines
US6651123B1 (en) 2000-03-30 2003-11-18 International Business Machines Corporation File system locking
US6534309B1 (en) 2000-08-03 2003-03-18 Cytokinetics, Inc. Motor proteins and methods for their use
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
BR0116452A (pt) 2000-12-21 2003-09-30 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP1517904A4 (fr) 2002-05-23 2007-02-21 Merck & Co Inc Inhibiteurs de kinesine mitotique
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP2305812A3 (fr) 2002-11-14 2012-06-06 Dharmacon, Inc. SIRNA fonctionnel et hyperfonctionnel
US7423018B2 (en) 2002-12-13 2008-09-09 University Of Massachusetts Kinesin-like proteins and methods of use
WO2004107618A2 (fr) 2003-05-23 2004-12-09 Wyeth Ligand du gitr et molecules et anticorps lies au ligand du gitr et leurs utilisations
AU2004255340B2 (en) 2003-07-08 2008-05-01 Novartis Ag Use of rapamycin and rapamycin derivatives for the treatment of bone loss
EP1660126A1 (fr) 2003-07-11 2006-05-31 Schering Corporation Agonistes ou antagonistes du recepteur du facteur de necrose tumorale induit par les glucocorticoides (gitr) ou de son ligand utilises dans le traitement des troubles immuns, des infections et du cancer
WO2005016252A2 (fr) 2003-07-11 2005-02-24 Ariad Gene Therapeutics, Inc. Macrocycles contenant du phosphore
TW200523262A (en) 2003-07-29 2005-07-16 Smithkline Beecham Corp Inhibitors of AKT activity
CA2534729A1 (fr) 2003-08-15 2005-02-24 Merck & Co., Inc. Inhibiteurs de kinesine mitotique
EP1692318A4 (fr) 2003-12-02 2008-04-02 Genzyme Corp Compositions et methodes pour le diagnostic et le traitement du cancer du poumon
RU2006124421A (ru) 2003-12-09 2008-01-20 ПРАВИТЕЛЬСТВО СОЕДИНЕННЫХ ШТАТОВ АМЕРИКИ, ПРЕДСТАВЛЕННОЕ СЕКРЕТАРЕМ ДЕПАРТАМЕНТА ЗДРАВООХРАНЕНИЯ И СЛУЖБЫ ДЛЯ ЛЮДЕЙ, УС Национальный Институт здравоохранени , Ведомство по передаче технологий (US) Способ подавления ответной иммунной реакции или лечения пролиферативного нарушения
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
US7504413B2 (en) 2004-05-06 2009-03-17 Cytokinetics, Inc. N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases
WO2006083289A2 (fr) 2004-06-04 2006-08-10 Duke University Methodes et compositions ameliorant l'immunite par depletion in vivo de l'activite cellulaire immunosuppressive
TW200612958A (en) * 2004-06-18 2006-05-01 Chiron Corp Substituted imidazole derivatives
AU2005273867B2 (en) 2004-08-18 2010-12-23 4Sc Ag Benzothienopyridines for use as inhibitors of Eg5 kinesin
DK1786785T3 (da) 2004-08-26 2010-05-31 Pfizer Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere
WO2006044453A1 (fr) 2004-10-13 2006-04-27 Wyeth Analogues de la 17-hydroxywortmannine employés en tant qu’inhibiteurs de pi3k
WO2006105021A2 (fr) 2005-03-25 2006-10-05 Tolerrx, Inc. Molecules de liaison gitr et leurs utilisations
US7829296B2 (en) 2005-04-25 2010-11-09 Ramot At Tel-Aviv University Ltd. Kinesin polypeptides, polynucleotides encoding same and compositions and methods of using same
EP2418278A3 (fr) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmée 1 (PD-1) et procédés de traitement du cancer à l'aide d'anticorps anti-PD-1 seuls ou combinés à d'autres formulations immunothérapeutiques
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2622870A1 (fr) 2005-09-20 2007-03-29 Pfizer Products Inc. Formes de dosage et procedes de traitement utilisant un inhibiteur de la tyrosine kinase
JP2009514866A (ja) * 2005-11-02 2009-04-09 サイトキネティクス・インコーポレーテッド ある種の化学物質、組成物、および方法
EP1981969A4 (fr) 2006-01-19 2009-06-03 Genzyme Corp Anticorps anti-gitr destines au traitement du cancer
WO2008007122A2 (fr) 2006-07-14 2008-01-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
WO2008015265A1 (fr) 2006-08-04 2008-02-07 Æterna Zentaris Gmbh Dérivés de l'anthracène et leur utilisation pour le traitement d'affections tumorales bénignes et malignes
BRPI0717923A2 (pt) 2006-12-07 2013-10-22 Genentech In '' composto, composição farmacêutica, método para tratar um câncer, processo para a produção de uma composição farmacêutica, usos, métodos para inibir ou modular a atividade da lipídeo quinase e kit ' '
CA2693677C (fr) 2007-07-12 2018-02-13 Tolerx, Inc. Therapies combinees utilisant des molecules de liaison au gitr
ES2537352T3 (es) 2007-09-12 2015-06-05 Genentech, Inc. Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapéuticos, y metodos para su uso
CA2701292C (fr) 2007-10-25 2015-03-24 Genentech, Inc. Procede de preparation de composes de thienopyrimidine
KR20110044992A (ko) 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＧＦ-β 길항제 다중-표적 결합 단백질
JPWO2010030002A1 (ja) 2008-09-12 2012-02-02 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
AR077033A1 (es) * 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
EP2295543A1 (fr) 2009-09-11 2011-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Procédé de préparation de virus de la grippe
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
ME02505B (fr) 2009-12-29 2017-02-20 Aptevo Res & Development Llc Protéines de liaison hétérodimères et utilisations de celles-ci
WO2011085261A1 (fr) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Inhibiteurs de hedgehog
CN102796103A (zh) * 2011-05-23 2012-11-28 南京英派药业有限公司 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用
WO2013039954A1 (fr) 2011-09-14 2013-03-21 Sanofi Anticorps anti-gitr
PT3031799T (pt) 2013-08-09 2018-07-04 Takeda Pharmaceuticals Co Composto aromático
JP2017517520A (ja) 2014-05-29 2017-06-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｗｅｅ１阻害剤を用いた癌を処置する方法
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
TW201643138A (zh) 2015-04-17 2016-12-16 佛瑪治療公司 作為組蛋白脫乙醯基酶（ｈｄａｃ）抑制劑之３－螺－７－異羥肟酸四氫萘
WO2016187508A2 (fr) 2015-05-20 2016-11-24 The Broad Institute Inc. Néo-antigènes partagés
BR112018069483A2 (pt) 2016-03-24 2019-07-30 Bayer Pharma AG pró-fármacos de medicamentos citotóxicos contendo grupos enzimaticamente cliváveis.
WO2019140380A1 (fr) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Agents de dégradation de protéines et utilisations associées
CN108768023B (zh) 2018-08-13 2020-01-07 珠海格力电器股份有限公司 转子组件及交替极电机
DE102018213662A1 (de) 2018-08-14 2020-02-20 Robert Bosch Gmbh Lautsprecher mit einem darin enthaltenen Leuchtelement
CN109039072B (zh) 2018-08-21 2020-09-08 南京南瑞继保电气有限公司 一种双极双向直流变换器及其控制方法和控制装置
JP2022513971A (ja) * 2018-12-20 2022-02-09 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
EP3897855B1 (fr) 2018-12-20 2023-06-07 Amgen Inc. Inhibiteurs de kif18a
CA3123227A1 (fr) * 2018-12-20 2020-06-25 Amgen Inc. Amides d'heteroaryle utiles en tant qu'inhibiteurs de kif18a
BR112021011989A2 (pt) 2018-12-20 2021-09-08 Amgen Inc. Inibidores de kif18a
JP2022527629A (ja) 2019-04-05 2022-06-02 アーリー・インコーポレイテッド 合成バイオマーカーのための改良された方法及び組成物
WO2020226333A1 (fr) 2019-05-03 2020-11-12 주식회사 디시젠 Méthode de prédiction et de pronostic du cancer et composition à cet effet
US20230093080A1 (en) 2019-07-15 2023-03-23 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2021026099A1 (fr) 2019-08-02 2021-02-11 Amgen Inc. Inhibiteurs de kif18a
EP4007756A1 (fr) 2019-08-02 2022-06-08 Amgen Inc. Inhibiteurs de kif18a
CA3146693A1 (fr) 2019-08-02 2021-02-11 Amgen Inc. Inhibiteurs de kif18a
CN114391012A (zh) 2019-08-02 2022-04-22 美国安进公司 作为kif18a抑制剂的吡啶衍生物
WO2021161323A1 (fr) 2020-02-16 2021-08-19 Genetikaplus Ltd. Procédés de pronostic thérapeutique
US12187992B2 (en) 2020-02-19 2025-01-07 The Regents Of The University Of California Method and device for early cancer screening
MX2022012992A (es) 2020-04-14 2022-11-08 Amgen Inc Inhibidores de kif18a para el tratamiento de enfermedades neoplasicas.
US20230233565A1 (en) 2020-05-11 2023-07-27 University Of Vermont A treatment approach involving kif18a inhibition for chromosomally unstable tumors
EP4237086A1 (fr) 2020-10-27 2023-09-06 Amgen Inc. Composés spiro hétérocycliques et procédés d'utilisation
WO2022214054A1 (fr) 2021-04-09 2022-10-13 Nanjing University Conjugué et son procédé de préparation et son utilisation
EP4361142A1 (fr) 2021-06-25 2024-05-01 Hangzhou Innogate Pharma Co., Ltd. Composé destiné à être utilisé en tant qu'inhibiteur de kif18a
TW202321213A (zh) 2021-07-21 2023-06-01 美商安進公司 Ｋｉｆ１８ａ抑制劑化合物之鹽和固態形式
IL310863A (en) 2021-08-26 2024-04-01 Volastra Therapeutics Inc KIF18A inhibitors in the spiro indoline form
CN118076586A (zh) 2021-09-16 2024-05-24 微境生物医药科技(上海)有限公司 Kif18a抑制剂
CN118201923A (zh) 2021-10-15 2024-06-14 海南先声再明医药股份有限公司 三环类化合物
KR20240108489A (ko) 2021-11-19 2024-07-09 위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드 Kif18a 저해제
WO2023146979A1 (fr) 2022-01-27 2023-08-03 The Board Of Trustees Of The Leland Stanford Junior University Plateforme de cytométrie de masse à cellule unique pour cartographier les effets d'agents candidats sur le cartilage
WO2023198209A1 (fr) 2022-04-15 2023-10-19 武汉人福创新药物研发中心有限公司 Inhibiteur de kif18a et son utilisation
US20230382889A1 (en) 2022-04-28 2023-11-30 Volastra Therapeutics, Inc. Compounds for inhibiting kif18a
WO2023212714A1 (fr) 2022-04-29 2023-11-02 Amgen Inc. Inhibition de kif18a pour le traitement du cancer

Also Published As

Publication number Publication date
IL283639A (en) 2021-07-29
US20220106293A1 (en) 2022-04-07
CA3123871A1 (fr) 2020-06-25
BR112021011989A2 (pt) 2021-09-08
AU2019403486A1 (en) 2021-06-24
PE20211475A1 (es) 2021-08-05
EA202191730A1 (ru) 2021-08-24
JP7407196B2 (ja) 2023-12-28
US20240317715A1 (en) 2024-09-26
SG11202106520VA (en) 2021-07-29
IL283639B1 (en) 2024-02-01
IL283639B2 (en) 2024-06-01
AR117490A1 (es) 2021-08-11
US11236069B2 (en) 2022-02-01
JOP20210154B1 (ar) 2023-09-17
US12054476B2 (en) 2024-08-06
SA521422303B1 (ar) 2023-12-11
JOP20210154A1 (ar) 2023-01-30
JP2022513972A (ja) 2022-02-09
UY38526A (es) 2020-06-30
CO2021008224A2 (es) 2021-07-30
US20200239441A1 (en) 2020-07-30
CL2021001634A1 (es) 2021-12-10
EP3897852A1 (fr) 2021-10-27
WO2020132648A1 (fr) 2020-06-25
CN113226473A (zh) 2021-08-06
MX2021007156A (es) 2021-08-16
PH12021551409A1 (en) 2022-05-16
TWI844602B (zh) 2024-06-11
CR20210387A (es) 2021-08-19
KR20210106474A (ko) 2021-08-30
TW202034924A (zh) 2020-10-01

Similar Documents

Publication Publication Date Title
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
IL269196A (en) Novel inhibitors
EP3788042A4 (fr) Inhibiteurs de bcl-2
EP3846674C0 (fr) Spéculum vaginal
MA52812A (fr) Inhibiteurs de sarm1
DK3740479T3 (da) Dna-pk-hæmmere
MA52413A (fr) Inhibiteurs de cd73
MA52635A (fr) Inhibiteurs de magl
MA53287A (fr) Inhibiteurs de prmt5
EP3817736A4 (fr) Inhibiteurs de pikfyve
DK3571192T3 (da) Jak1-selektive inhibitorer
MA52813A (fr) Inhibiteurs de sarm1
MA52809A (fr) Inhibiteurs de sarm1
DK3630744T3 (da) Pyrazol-magl-inhibitorer
EP3786157A4 (fr) Inhibiteur de l'interaction protéine-protéine mll1-wdr5 de phényle triazole
EP3833664A4 (fr) Inhibiteurs de smad3
EP3706742A4 (fr) Inhibiteurs de prmt5
EP3760771A4 (fr) Multifilament de polyamide 610
EP3600301A4 (fr) Inhibiteurs de kdm4
EP3891095C0 (fr) Opale polymère
MA51611A (fr) Inhibiteurs de pi4kiiibêta
EP3883918A4 (fr) Inhibiteurs de rip1
EP3878374A4 (fr) Dispositif d'occlusion
EP3805997A4 (fr) Nanocomprimé lipidique